Anixa Biosciences Inc logo

Anixa Biosciences Inc

0000715446

Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer. Their portfolio includes CAR-T immunotherapy and vaccines targeting breast, ovarian, lung, colon, and prostate cancers. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. They are committed to addressing intractable cancers.

85
Meget Pålidelig
Tillidsscore

Officielt Register

Momsnummer
112622630
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA 95118
Branchekoder
Pharmaceutical Preparations, 2834

AI Kvalitetsanalyse

Branche
Biotechnology
SSL/HTTPS
Sikker
Professionel E-mail
Nej

Tillidsscore Detaljer

Register Verificeret35/35
Kvalitetsscore50/60
Nyhedsanalyse0/5

Genveje

Sidst opdateret: 1/2/2026

🌟 Lignende Troværdige Virksomheder

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Meget Pålidelig

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, USA
Se profil

AGENUS INC

AGENUS INC logo
86/100 · Meget Pålidelig

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

3 FORBES ROAD, USA
Se profil

Evaxion A/S

Evaxion A/S logo
77/100 · Pålidelig

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, USA
Se profil